Metronidazole
Bismuth / Metronidazole / Tetracycline, Flagyl, Likmez, Metro, Metrocream, Metrogel, Metrolotion, Metronidazole, Noritate, Nuvessa, Pylera, Vandazole (metronidazole) is a small molecule pharmaceutical. Metronidazole was first approved as Flagyl i.v. rtu in plastic container on 1982-01-01. It is used to treat abscess, amebiasis, bacterial endocarditis, bacterial infections, and bacterial meningitis amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Flagyl, Likmez, Metro, Metrocream, Metrogel, Metrolotion, Metronidazole, Noritate, Nuvessa, Vandazole (discontinued: Flagyl, Metro, Metrogel, Metronidazole, Protostat, Satric)
CombinationsBismuth subcitrate potassium, metronidazole tetracycline, Bismuth subsalicylate, metronidazole tetracycline (discontinued: Helidac)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Metronidazole
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| METRO I.V. IN PLASTIC CONTAINER | B. Braun Medical | N-018900 RX | 1983-09-29 | 1 products, RLD, RS |
| METROGEL-VAGINAL | Bausch Health Companies | N-020208 RX | 1992-08-17 | 1 products, RLD, RS |
| NORITATE | Bausch Health Companies | N-020743 RX | 1997-09-26 | 1 products, RLD, RS |
| FLAGYL I.V. RTU IN PLASTIC CONTAINER | Baxter | N-018657 RX | 1982-01-01 | 1 products, RLD, RS |
| NUVESSA | CHEMO Research | N-205223 RX | 2014-03-24 | 1 products, RLD, RS |
| METROCREAM | Galderma | N-020531 RX | 1995-09-20 | 1 products, RLD, RS |
| METROGEL | Galderma | N-021789 RX | 2005-06-30 | 1 products, RLD, RS |
| METROLOTION | Galderma | N-020901 RX | 1998-11-24 | 1 products, RLD, RS |
| METRONIDAZOLE IN PLASTIC CONTAINER | Hospira | N-018890 RX | 1983-11-18 | 1 products, RLD, RS |
| FLAGYL | Pfizer | N-020334 RX | 1995-05-03 | 1 products, RLD, RS |
Show 2 marketed
Show 17 discontinued
Metronidazole hydrochloride
Bismuth subsalicylate
+
Metronidazole
+
Tetracycline hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| HELIDAC | Casper Pharma | N-050719 DISCN | 1996-08-15 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| 171083 ivermectin 1% / metronidazole 1% / niacinamide 4% | unapproved drug other | 2020-07-02 |
| aceast clear concealer sunscreen liquid foundation spf50 pa | C200263 | 2024-10-10 |
| acnil | unapproved drug other | 2025-02-17 |
| bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride | ANDA | 2024-12-27 |
| bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride | New Drug Application | 2024-07-25 |
| bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride | ANDA | 2024-10-22 |
| bismuth subsalicylate/metronidazole/tetracycline hydrochloride | ANDA | 2019-11-24 |
| brimonidine tartrate 0.25% / ivermectin 1% / metronidazole 1% / niacinamide 4% | unapproved drug other | 2019-05-15 |
| flagyl | New Drug Application | 2024-12-26 |
| helidac therapy | ANDA | 2020-06-17 |
Show 22 more
Indications
FDA
EMA
Show 28 more
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Metronidazole, Likmez, Saptalis Pharms | |||
| 11541035 | 2039-10-04 | DP | |
| Metronidazole, Nuvessa, Chemo Research Sl | |||
| 8946276 | 2032-06-28 | U-1664 | |
| 9198858 | 2032-06-28 | U-1664 | |
| 10238634 | 2032-06-28 | DP | |
| 10596155 | 2032-06-28 | DP | |
| 8658678 | 2028-06-27 | U-1682 | |
| 7893097 | 2028-02-19 | DP | |
| 8877792 | 2028-02-02 | DP | |
| Metronidazole, Vandazole, Teva Pharms | |||
| 7456207 | 2024-09-22 | DP | |
ATC Codes
A: Alimentary tract and metabolism drugs
— A01: Stomatological preparations
— A01A: Stomatological preparations
— A01AB: Antiinfectives and antiseptics for local oral treatment
— A01AB17: Metronidazole
— A02: Drugs for acid related disorders
— A02B: Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)
— A02BD: Combinations for eradication of helicobacter pylori
— A02BD01: Omeprazole, amoxicillin and metronidazole
— A02BD02: Lansoprazole, tetracycline and metronidazole
— A02BD03: Lansoprazole, amoxicillin and metronidazole
— A02BD08: Bismuth subcitrate, tetracycline and metronidazole
— A02BD11: Pantoprazole, amoxicillin, clarithromycin and metronidazole
— A02BD13: Rabeprazole, amoxicillin and metronidazole
— A02BD15: Vonoprazan, amoxicillin and metronidazole
D: Dermatologicals
— D06: Antibiotics and chemotherapeutics for dermatological use
— D06B: Chemotherapeutics for topical use
— D06BX: Other chemotherapeutics in atc
— D06BX01: Metronidazole
G: Genito urinary system and sex hormones
— G01: Gynecological antiinfectives and antiseptics
— G01A: Antiinfectives and antiseptics, excl. combinations with corticosteroids
— G01AF: Imidazole derivatives, gyncological antiinfectives
— G01AF01: Metronidazole
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01R: Combinations of antibacterials
— J01RA: Combinations of antibacterials
— J01RA03: Cefuroxime and metronidazole
— J01RA04: Spiramycin and metronidazole
— J01RA10: Ciprofloxacin and metronidazole
— J01RA14: Norfloxacin and metronidazole
— J01X: Other antibacterials in atc
— J01XD: Imidazole derivatives, antibacterial for systemic use
— J01XD01: Metronidazole
P: Antiparasitic products, insecticides and repellents
— P01: Antiprotozoals
— P01A: Agents against amoebiasis and other protozoal diseases
— P01AB: Nitroimidazole derivatives, antiprotozoal agents against amoebiasis and other protozoal diseases
— P01AB01: Metronidazole
— P01AB51: Metronidazole and furazolidone
— P01AB52: Metronidazole and diloxanide
HCPCS
Code | Description |
|---|---|
| S0030 | Injection, metronidazole, 500 mg |
Clinical
Clinical Trials
1159 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 1 | 1 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | — | 1 | 1 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | — | — | 1 | 1 |
| Hypoglycemia | D007003 | — | E16.2 | — | — | — | — | 1 | 1 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Metronidazole |
| INN | metronidazole |
| Description | Metronidazole is a member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death. It has a role as an antitrichomonal drug, a prodrug, an antibacterial drug, an antimicrobial agent, an antiparasitic agent, a xenobiotic, an environmental contaminant, a radiosensitizing agent and an antiamoebic agent. It is a member of imidazoles, a C-nitro compound and a primary alcohol. It is a conjugate base of a metronidazole(1+). |
| Classification | Small molecule |
| Drug class | antiprotozoal substances (metronidazole type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1ncc([N+](=O)[O-])n1CCO |
Identifiers
| PDB | — |
| CAS-ID | 443-48-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL137 |
| ChEBI ID | 6909 |
| PubChem CID | 4173 |
| DrugBank | DB00916 |
| UNII ID | 140QMO216E (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Metronidazole
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 66,683 documents
View more details
Safety
Black-box Warning
Black-box warning for: Bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, Bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride, Bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride, Bismuth subsalicylate/metronidazole/tetracycline hydrochloride, Flagyl, Helidac therapy, Likmez, Metronidazole, Metronidazole250 mg, Metronidazole500 mg, Pylera
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
35,896 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use